Risk Assessment of Drug-Induced Lysosomal Dysfunction

Abstract

Drug-induced lysosomal dysfunction represents an underrecognized but increasingly important adverse effect of numerous therapeutic agents, with broad implications for cellular homeostasis and patient safety. This review comprehensively examines the epidemiology, mechanisms, clinical manifestations, diagnostic strategies, and management of drug-induced lysosomal dysfunction, integrating recent evidence and expert recommendations to provide clinicians with a robust foundation for risk assessment and patient care.

Introduction

Lysosomes are essential organelles that regulate cellular clearance, metabolism, and signaling by orchestrating the breakdown of biomolecules. Disruption of lysosomal function by medications—referred to as drug-induced lysosomal dysfunction—can precipitate a spectrum of clinical consequences, ranging from subclinical metabolic derangements to overt organ dysfunction. As new therapeutics and polypharmacy become more prevalent, recognizing the risk and clinical impact of drug-induced lysosomal impairment has become critical for healthcare professionals.

Epidemiology / Disease Burden

Although the precise incidence of drug-induced lysosomal dysfunction is difficult to ascertain due to underdiagnosis and variable clinical presentations, emerging pharmacovigilance data highlight increasing reports across multiple drug classes. Cationic amphiphilic drugs (CADs), including certain antidepressants, antimalarials, and antiarrhythmics, are most commonly implicated. The true disease burden is likely underestimated, with many cases manifesting as nonspecific symptoms or being misattributed to comorbid conditions. Recent systematic reviews suggest that lysosomal dysfunction contributes to adverse drug reactions in various populations, including transplant recipients and oncology patients, underscoring the need for greater awareness and surveillance.

Pathophysiology

The mechanistic basis of drug-induced lysosomal dysfunction involves several intersecting pathways. Many culprit drugs accumulate within lysosomes by virtue of their physicochemical properties—most notably, their cationic and amphiphilic nature—leading to phospholipidosis, impaired acidification, and disruption of hydrolase activity. This can result in defective autophagy, accumulation of undegraded substrates, and secondary oxidative stress. In some cases, drugs directly inhibit lysosomal enzymes or compromise membrane integrity, further exacerbating cellular injury. The downstream effects can impair organ systems with high metabolic turnover, such as the liver, kidney, and nervous system.

Risk Factors

Several risk factors increase the likelihood of developing drug-induced lysosomal dysfunction. These include exposure to high-risk medications (notably CADs, statins, and certain chemotherapeutics), genetic predispositions affecting lysosomal enzyme activity, advanced age, polypharmacy, and pre-existing metabolic or lysosomal storage disorders. Renal or hepatic impairment may further elevate risk by altering drug pharmacokinetics and increasing tissue exposure. Notably, pharmacogenomic studies have identified variants in genes encoding lysosomal proteins that may modulate individual susceptibility, although routine screening is not yet standard practice.

Clinical Features

Clinical manifestations of drug-induced lysosomal dysfunction are heterogeneous and often organ-specific. Common presentations include hepatomegaly, elevated transaminases, renal tubular dysfunction, peripheral neuropathy, and myopathy. Pulmonary phospholipidosis, characterized by accumulation of foamy macrophages, can manifest as dyspnea or interstitial lung disease. In severe cases, progressive multi-organ failure may develop. Subclinical forms may be detected incidentally through laboratory abnormalities or imaging studies, emphasizing the importance of vigilance in at-risk populations.

Diagnosis

Diagnosis of drug-induced lysosomal dysfunction requires a high index of suspicion and a multidisciplinary approach. Laboratory investigations may reveal elevated biomarkers of organ dysfunction, while imaging (e.g., MRI, CT) can demonstrate characteristic tissue changes such as lipid-laden cells or organomegaly. Definitive diagnosis often relies on tissue biopsy with electron microscopy to identify lysosomal inclusions or phospholipidosis. Ancillary tests, such as measurement of lysosomal enzyme activity or emerging biomarkers (e.g., chitotriosidase), may support the diagnosis. Importantly, a thorough medication history is essential for attributing causality.

Treatment & Management

The cornerstone of management is prompt cessation or substitution of the offending agent. Supportive measures are tailored to the affected organ system, ranging from hepatoprotective strategies to renal replacement therapy in severe cases. In select scenarios, pharmacological interventions targeting lysosomal biogenesis or autophagy modulation (e.g., mTOR inhibitors) have shown promise, although robust clinical data are limited. Close monitoring of organ function and judicious use of alternative medications are critical during the recovery period. Patient education and multidisciplinary collaboration enhance safety and long-term outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed advances in the understanding and management of drug-induced lysosomal dysfunction. High-throughput screening technologies and omics-based approaches are enabling earlier detection of lysosomal impairment. Novel biomarkers, such as lysosphingolipids and autophagy-related proteins, offer potential for non-invasive monitoring. Therapeutically, agents that enhance lysosomal function or mitigate phospholipidosis are under investigation, including small-molecule chaperones and gene-based therapies. Efforts to personalize treatment based on pharmacogenomics and individual risk profiles represent promising frontiers in reducing the clinical impact of this adverse drug effect.

Guideline Recommendations

Expert consensus and emerging guidelines emphasize the importance of proactive risk assessment for drug-induced lysosomal dysfunction, particularly when initiating high-risk medications or treating vulnerable populations. Recommendations include baseline and periodic monitoring of organ function, patient education regarding symptom recognition, and prompt evaluation of unexplained laboratory or clinical findings. Where feasible, alternative agents with lower lysosomal toxicity should be prioritized, and multidisciplinary input sought for complex cases. Ongoing pharmacovigilance and reporting are essential to refine risk stratification and inform future guidelines.

Conclusion

Drug-induced lysosomal dysfunction is a clinically significant and potentially preventable complication of pharmacotherapy with wide-ranging implications for patient safety. Enhanced recognition, risk stratification, and evidence-based management can mitigate adverse outcomes and improve therapeutic decision-making. Continued research into pathophysiology, biomarkers, and targeted interventions will further inform clinical practice, ensuring optimal care for patients exposed to lysosome-impairing drugs.